Instil Bio Q4 Adj EPS $(1.26) Beats $(2.85) Estimate
Portfolio Pulse from Benzinga Newsdesk
Instil Bio reported a Q4 adjusted EPS loss of $(1.26), surpassing the analyst consensus estimate of $(2.85) by 55.79%.
March 21, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Instil Bio reported a Q4 adjusted EPS loss of $(1.26), which was significantly better than the expected $(2.85) loss.
Instil Bio's Q4 earnings significantly exceeded analyst expectations, which could lead to positive investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100